126 related articles for article (PubMed ID: 36798262)
1. Effect of Total Sphingomyelin Synthase Activity on Low Density Lipoprotein Catabolism in Mice.
Li Z; He M; Chen G; Worgall TS; Jiang XC
bioRxiv; 2023 Feb; ():. PubMed ID: 36798262
[TBL] [Abstract][Full Text] [Related]
2. Effect of Total SMS Activity on LDL Catabolism in Mice.
Li Z; He M; Chen G; Souaiaia T; Worgall TS; Jiang XC
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1251-1261. PubMed ID: 37128925
[TBL] [Abstract][Full Text] [Related]
3. Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.
Li Z; Chiang YP; He M; Zhang K; Zheng J; Wu W; Cai J; Chen Y; Chen G; Chen Y; Dong J; Worgall TS; Jiang XC
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 May; 1866(5):158898. PubMed ID: 33545384
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
[TBL] [Abstract][Full Text] [Related]
5. Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice.
Liu J; Zhang H; Li Z; Hailemariam TK; Chakraborty M; Jiang K; Qiu D; Bui HH; Peake DA; Kuo MS; Wadgaonkar R; Cao G; Jiang XC
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):850-6. PubMed ID: 19286635
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice.
Dong J; Liu J; Lou B; Li Z; Ye X; Wu M; Jiang XC
J Lipid Res; 2006 Jun; 47(6):1307-14. PubMed ID: 16508036
[TBL] [Abstract][Full Text] [Related]
7. Impact of sphingomyelin synthase 1 deficiency on sphingolipid metabolism and atherosclerosis in mice.
Li Z; Fan Y; Liu J; Li Y; Huan C; Bui HH; Kuo MS; Park TS; Cao G; Jiang XC
Arterioscler Thromb Vasc Biol; 2012 Jul; 32(7):1577-84. PubMed ID: 22580896
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated sphingomyelin synthase 2 increases atherosclerotic lesions in ApoE KO mice.
Wang X; Dong J; Zhao Y; Li Y; Wu M
Lipids Health Dis; 2011 Jan; 10():7. PubMed ID: 21235823
[TBL] [Abstract][Full Text] [Related]
9. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.
Li Y; Dong J; Ding T; Kuo MS; Cao G; Jiang XC; Li Z
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1513-20. PubMed ID: 23640498
[TBL] [Abstract][Full Text] [Related]
10. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.
Liu J; Huan C; Chakraborty M; Zhang H; Lu D; Kuo MS; Cao G; Jiang XC
Circ Res; 2009 Jul; 105(3):295-303. PubMed ID: 19590047
[TBL] [Abstract][Full Text] [Related]
11. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
[TBL] [Abstract][Full Text] [Related]
12. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis.
Ding T; Li Z; Hailemariam T; Mukherjee S; Maxfield FR; Wu MP; Jiang XC
J Lipid Res; 2008 Feb; 49(2):376-85. PubMed ID: 17982138
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation.
Matsumoto G; Hashizume C; Watanabe K; Taniguchi M; Okazaki T
Mol Med; 2019 Dec; 25(1):56. PubMed ID: 31847800
[TBL] [Abstract][Full Text] [Related]
14. Subcellular targeting domains of sphingomyelin synthase 1 and 2.
Yeang C; Ding T; Chirico WJ; Jiang XC
Nutr Metab (Lond); 2011 Dec; 8():89. PubMed ID: 22168400
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms involved in cellular ceramide homeostasis.
Hussain MM; Jin W; Jiang XC
Nutr Metab (Lond); 2012 Jul; 9(1):71. PubMed ID: 22849442
[TBL] [Abstract][Full Text] [Related]
16. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis.
Fan Y; Shi F; Liu J; Dong J; Bui HH; Peake DA; Kuo MS; Cao G; Jiang XC
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2114-20. PubMed ID: 20814016
[TBL] [Abstract][Full Text] [Related]
17. Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells.
Tafesse FG; Huitema K; Hermansson M; van der Poel S; van den Dikkenberg J; Uphoff A; Somerharju P; Holthuis JC
J Biol Chem; 2007 Jun; 282(24):17537-47. PubMed ID: 17449912
[TBL] [Abstract][Full Text] [Related]
18. Development of a quantitative biochemical and cellular sphingomyelin synthase assay using mass spectrometry.
Chen Y; Yurek DA; Yu L; Wang H; Ehsani ME; Qian YW; Konrad RJ; Jiang XC; Kuo MS; Cao G; Wang J
Anal Biochem; 2013 Jul; 438(1):61-6. PubMed ID: 23535273
[TBL] [Abstract][Full Text] [Related]
19. A sensitive cell-based method to screen for selective inhibitors of SMS1 or SMS2 using HPLC and a fluorescent substrate.
Zama K; Mitsutake S; Watanabe K; Okazaki T; Igarashi Y
Chem Phys Lipids; 2012 Oct; 165(7):760-8. PubMed ID: 23063490
[TBL] [Abstract][Full Text] [Related]
20. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor.
Li Y; Huang T; Lou B; Ye D; Qi X; Li X; Hu S; Ding T; Chen Y; Cao Y; Mo M; Dong J; Wei M; Chu Y; Li H; Jiang XC; Cheng N; Zhou L
Eur J Med Chem; 2019 Feb; 163():864-882. PubMed ID: 30580239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]